GlassScriptPhysician profile
Nina Ni
NPI 1780959734
$942.97
in general payments reported to CMS, 2019-2025
15 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $56.48 · 2021: $233 · 2022: $113 · 2023: $146 · 2024: $103 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $463.08 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Dompe US, INC. | $98.10 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $56.03 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Biotissue Holdings INC. | $44.92 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $38.12 | 2024-2025 | Xdemvy |
| Abbvie INC. | $37.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $31.17 | 2020-2022 | |
| Sight Sciences, INC. | $30.84 | 2022-2024 | Tearcare System |
| Oyster Point Pharma, INC. | $30.17 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $23.91 | 2023 | Tepezza |
| Amgen INC. | $22.07 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $19.93 | 2024 | Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $16.25 | 2025 | |
| Aerie Pharmaceuticals, INC. | $15.60 | 2021 | |
| Thea Pharma INC. | $14.97 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Ni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.